Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
N Engl J Med
; 390(14): 1290-1298, 2024 Apr 11.
Article
en En
| MEDLINE
| ID: mdl-38477966
ABSTRACT
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.).
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Receptores de Antígenos de Linfocitos T
/
Inmunoterapia Adoptiva
/
Glioblastoma
/
Receptores ErbB
/
Receptores Quiméricos de Antígenos
Límite:
Humans
Idioma:
En
Revista:
N Engl J Med
Año:
2024
Tipo del documento:
Article
País de afiliación:
Antillas Neerlandesas